Pipeline

We are building a deep pipeline of potentially differentiated therapies, with the goal of advancing care and outcomes for patients with diverse inflammatory diseases

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

CBP-201*

Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Atopic Dermatitis (AD)
  •  
  •  
  •  
  •  
  •  
Atopic Dermatitis (AD)
Asthma
  •  
  •  
  •  
  •  
  •  
Asthma

CBP-307

Small molecule targeting S1P1
(Th1 cell modulator)

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Ulcerative Colitis (UC)
  •  
  •  
  •  
  •  
  •  
Ulcerative Colitis (UC)
Crohn's Disease (CD)
  •  
  •  
  •  
  •  
  •  
Crohn's Disease (CD)

CBP-174

Peripherally restricted
H3 receptor antagonist

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Pruritus Associated with AD
  •  
  •  
  •  
  •  
  •  
Pruritus Assoc.
with AD
* CBP-201 Ph2 trial in nasal polyps was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.
  • Key:
  • Ongoing
  • Planned
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors